Neuroderm Ltd.
- Address
- Bell Entrance, Floor 4, 3 Pekeris Street
Sponsor Overview
Specializations
Parkinson’s disease
Neuroderm Ltd. focuses its clinical research on Parkinson’s disease, with particular attention to motor fluctuations and the management of daily ON/OFF periods in people living with advanced disease.
- Parkinson’s disease
- Motor fluctuations
- ON/OFF diary assessment
The sponsor’s studies are directed toward improving symptom control in patients experiencing variable response to treatment, with emphasis on maintaining functional time during the day.
Continuous subcutaneous infusion
Another major area of interest is continuous subcutaneous infusion for Parkinson’s disease, examining sustained delivery approaches intended to support steadier therapeutic exposure in advanced neurological care.
- Subcutaneous infusion
- Advanced Parkinson’s disease
- Continuous delivery therapy
Research in this domain reflects a therapeutic focus on non-oral administration routes for patients with complex treatment needs.
Safety and tolerability
Neuroderm Ltd. also places strong emphasis on the long-term safety, local tolerability, and systemic tolerability of therapies used in Parkinson’s disease, particularly for continuous infusion treatments.
- Long-term safety
- Local tolerability
- Systemic tolerability
This area supports the evaluation of treatment durability in patients requiring ongoing neurological management.
Comparison with oral therapy
The sponsor’s research landscape includes comparison of continuous subcutaneous treatment with oral therapy in Parkinson’s disease, highlighting interest in treatment alternatives for people whose symptoms are not adequately controlled by standard oral regimens.
- Oral treatment comparison
- Symptom control
- Advanced therapy options
These studies are centered on clinical outcomes relevant to daily functioning and treatment experience in neurological disease care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion Versus Oral Immediate-Release Carbidopa-Levodopa in Parkinson's Disease with Motor Fluctuations |  Austria Belgium Czechia France Italy Poland Portugal Slovakia Spain | Not Recruiting |
| Long-Term Safety Evaluation of Continuous Subcutaneous Infusion of ND0612 (Carbidopa/Levodopa) in Advanced Parkinson's Disease | Austria France Italy Poland | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 36 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
36 centres- Address
- 264 Rue Saint Pierre, 13005 Marseille
- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
- Address
- Via Senese 169, 58100 Arezzo
- Address
- Lugar De Sete Fontes S Victor, 4710-243 Braga
- Address
- Avenue Des Tamaris, 13100 Aix En Provence
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Neuroderm Ltd..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.